Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend

Summit Therapeutics' HARMONi Phase 3 trial for ivonescimab initially claimed consistent progression-free survival (PFS) benefits across Chinese and Western populations, but detailed longer-term data revealed a notable divergence, with Western patients showing a 33% PFS improvement versus 45% for Chinese patients. While the trial missed its primary overall survival (OS) endpoint, a subsequent longer-term OS analysis, particularly for the ex-China cohort, demonstrated improved nominal statistical significance (p=0.0332 overall) and growing consistency, which Summit suggests could still pave the way for FDA approval. This development underscores the ongoing scrutiny of China-derived clinical data's applicability for global regulatory submissions.

Analysis

Summit Therapeutics' ivonescimab presents a complex and high-risk investment profile following the detailed readout from its HARMONi Phase 3 trial. Initial reports of a 48% progression-free survival (PFS) benefit and claims of consistent efficacy between Chinese and Western populations have been significantly tempered. Longer-term follow-up data revealed a material divergence, with a 33% PFS benefit in Western patients compared to 45% in Chinese patients—a 12-percentage-point gap that analysts from firms like Leerink Partners have described as problematic. Critically, the trial missed its dual primary endpoint for overall survival (OS), reporting a p-value of 0.057 against a significance threshold of 0.0448, a major setback given the FDA has indicated that a statistically significant OS benefit is necessary for approval. Summit's case now hinges on a more recent, exploratory OS analysis with a longer 13.7-month follow-up for the Western cohort, which showed an improved hazard ratio (HR 0.98) and a nominal p-value of 0.0332. While this new data is encouraging and forms the basis of the company's argument for maturing and consistent results, it is not from a prospectively defined analysis, meaning its regulatory weight is uncertain. The path to approval relies heavily on the FDA's willingness to accept a post-hoc analysis of a non-statistically powered subgroup, creating a significant binary risk for the asset.

Key Decisions for Investors

• Investors should treat Summit Therapeutics (SMMT) as a high-risk, event-driven holding, as its valuation is almost entirely dependent on a discretionary FDA approval for ivonescimab based on mixed clinical data.
• Monitor any updates on the maturing overall survival (OS) data from the Western patient cohort, as a continued positive trend is the company's central argument to overcome the trial's failure to meet its primary OS endpoint.
• The 12-percentage-point efficacy gap in progression-free survival between Chinese and Western patients should be considered a major regulatory risk that could undermine the drug's perceived global applicability.
• Given the missed primary endpoint and reliance on post-hoc analysis, risk-averse investors should exercise extreme caution, while those maintaining a position must be prepared for significant volatility pending clarity on the FDA submission strategy and subsequent regulatory feedback.